Incidence of Second Malignancy in Patients with Papillary Thyroid Cancer from Surveillance, Epidemiology, and End Results 13 Dataset
Table 1
Prevalence of primary second malignancy in papillary thyroid cancer survivors, SEER 13 cohort.
Observed
Expected
O/E
95% CI
Excess risk
Mean age at event
All sites
3,200
2,749.03
1.16#
1.12–1.21
13.15
64.45
All solid tumors
2,839
2,464.99
1.15#
1.11–1.19
10.91
64.38
Salivary Gland
28
6.74
4.15#
2.76–6.0
0.62
56.91
Large intestine
3
9.98
0.30#
0.06–0.88
−0.2
75.42
Rectum
32
52.95
0.60#
0.41–0.85
−0.61
60.12
Rectum, rectosigmoid junction, anus, anal canal and anorectum
63
83.41
0.76#
0.58–0.97
−0.6
62.89
Bones and joints
14
3.29
4.26#
2.33–7.15
0.31
58.44
Soft tissue including heart
31
15.93
1.95#
1.32–2.76
0.44
60.84
Skin excluding basal and squamous
182
129.47
1.41#
1.21–1.63
1.53
61.53
Melanoma of the skin
162
118.65
1.37#
1.16–1.59
1.26
61.02
Breast
727
621.47
1.17#
1.09–1.26
3.08
61.06
Prostate
316
259.04
1.22#
1.09–1.36
1.66
67.38
Urinary bladder
129
99.46
1.30#
1.08–1.54
0.86
71.92
Kidney
152
70.32
2.16#
1.83–2.53
2.38
63.68
Ureter
8
2.94
2.72#
1.17–5.36
0.15
74.16
All lymphatic and hematopoietic diseases
294
224.83
1.31#
1.16–1.47
2.02
64.78
Lymphoma
147
122.31
1.20#
1.02–1.41
0.72
64.15
Hodgkin lymphoma
11
9.61
1.14
NS
0.04
38.58
Non-Hodgkin lymphoma
136
112.69
1.21#
1.01–1.43
0.68
66.22
Myeloma
44
35.26
1.25
NS
0.25
71.5
Leukemia
103
67.26
1.53#
1.25–1.86
1.04
62.81
Lymphocytic leukemia
45
32.74
1.37#
1–1.84
0.36
63.81
Acute lymphocytic leukemia
13
3.27
3.98#
2.12–6.8
0.28
58.2
Chronic lymphocytic leukemia
32
27.42
1.17
NS
0.13
66.09
Nonlymphocytic leukemia
58
34.52
1.68#
1.28–2.17
0.68
62.04
Acute nonlymphocytic leukemia (ANLL)
40
23.15
1.73#
1.23–2.35
0.49
63.89
Myeloid and monocytic leukemia
55
31.41
1.75#
1.32–2.28
0.69
61.09
Acute myeloid leukemia
38
20.59
1.85#
1.31–2.53
0.51
65.06
Cancers without statistically significant elevated risk are excluded, except for ones related to other statistically significant cancers; #: value < 0.05; 95% CI: 95% confidence interval; NS: statistically not significant.
